SCHEMBL6301253

SCHEMBL6301253

COC(=O)c1ccc2c(n1)nc(C)n2Cc1ccc(SC)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
TP53 P04637 2/20 0.37
DCTPP1 Q9H773 2/20 0.37
KDM4E B2RXH2 1/20 0.36
BRD4 O60885 2/20 0.36
KIF11 P52732 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGER4 P35408 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
PPARG P37231 2/20 0.35
ABL1 P00519 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
RIN1 Q13671 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6299634 0.88 MAPT (0.39) MAPTTP53DCTPP1KDM4EBRD4
SCHEMBL6301746 0.88 PPARG (0.45) MAPTTP53DCTPP1RAB9APPARG
SCHEMBL6301336 0.86 ABL1 (0.44) MAPTTP53DCTPP1KDM4EMEN1
SCHEMBL6299003 0.86 MAPT (0.52) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL6306166 0.86 PLA2G2A (0.43) MAPTTP53DCTPP1KDM4EMEN1
SCHEMBL6300120 0.86 MAPT (0.38) MAPTTP53DCTPP1KDM4EBRD4
SCHEMBL6299206 0.84 DCTPP1 (0.40) MAPTTP53DCTPP1KDM4EBRD4
SCHEMBL6299267 0.84 DCTPP1 (0.43) MAPTTP53DCTPP1KDM4EMEN1
SCHEMBL6305762 0.84 MAPT (0.39) MAPTTP53DCTPP1KDM4EKIF11
SCHEMBL6298828 0.84 MAPT (0.37) MAPTTP53DCTPP1KDM4EBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 MAPT 4591/4885TP53 4884/4885DCTPP1 2223/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM MAPT 4725/4885TP53 4849/4885DCTPP1 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.